Drug intelligence / Profile preview

Folinozit

Development stage: Phase 4
Lead developer: Nafas Zist Pharmed
Modality: Small Molecules
Administration: Oral

Overview

Folinozit is a nutritional supplement developed by Nafas Zist Pharmed, specifically formulated for the management of polycystic ovary syndrome (PCOS), insulin resistance, type 2 diabetes, and associated infertility. It is a combination product typically composed of myo-inositol and folic acid. Myo-inositol acts as a precursor for inositol phosphoglycans, which serve as second messengers in insulin and follicle-stimulating hormone (FSH) signaling pathways. This mechanism helps to improve insulin sensitivity, reduce compensatory hyperinsulinemia, and restore normal ovulatory cycles in women with PCOS. Folic acid is included to support DNA synthesis and cellular division, which is critical for reproductive health and the prevention of neural tube defects during early pregnancy.

Brand names: Folinozit
Other names: myo-inositol + folic acid

Beyond the preview

Go deeper on Folinozit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Folinozit.